undamentalytics Newsletter

Sohn Catherine A.: insider trades

Director at 3 companies we cover. 1 open-market purchase and 13 sales not made under a pre-set plan, reported from August 14, 2013 to January 8, 2026.

Would copying Sohn Catherine A.’s purchases have beaten the S&P 500?

Too few purchases to judge. Only 1 purchase has 12 months of prices after the report; we judge insiders once they have 20. The figures below can swing a long way on a handful of trades. Buying each purchase the day after it was reported, an equal amount each, and holding it 12 months or until they reported a sale would have turned $10,000 on January 14, 2019 into $11,474 by November 2, 2026, +1.8% a year. The copy held shares only 13% of the time, so the fair comparison is the S&P 500 on those same days with Treasury bills otherwise: $15,868, +6.1% a year (the S&P 500 held throughout made $32,934, +16.6% a year). Beta against the index was 0.03. Twelve months after each report, the average purchase was −35.9% against the S&P 500 (median −35.9%), and 0% beat it. Measured from the trade date, the insider’s own timing, the average was −38.0%. After their sales, the shares moved −10.6% against the index over 12 months on average (a negative figure means selling was the right call); 67% trailed it.

With 296 insiders tested, some will look skilled or unskilled by chance alone: when we replaced each insider’s stocks with random companies bought on the same days, about 5.7 cleared the bar ahead and 23.3 behind. One record on its own proves little.

$0$10.0k$20.0k$30.0k 20192020202120222023202420252026 $32.9k$15.9k$11.5k
Copying Sohn Catherine A.S&P 500, same days investedS&P 500, held throughout $10,000 copying Sohn Catherine A.’s open-market purchases from January 14, 2019, before costs and taxes, marked weekly. Each purchase gets the same starting stake, bought at the close of the first trading day after the report and sold 12 months later or the day after a reported sale of that stock; uninvested money earns the Treasury bill rate. “Same days invested” holds the S&P 500 only on the days the copy held shares, Treasury bills otherwise.
Return a year, copying
+1.8%
S&P 500, same days invested
+6.1% (held throughout +16.6%)
Time in shares
13%
Sharpe ratio (S&P 500)
−0.02 (0.75)
Biggest drop (S&P 500)
−30% (−34%)
Market sensitivity (beta)
0.03
Purchases copied
1

Trade by trade

Sohn Catherine A.: trades against the S&P 500 afterwards
MeasuredTrades countedAverage vs S&P 500MedianWent the right wayYearst-statisticp-valueEvidence
Purchases, 3 months after the report 1 −24.8% −24.8% 0% 1 — — Not enough years
Purchases, 6 months after the report 1 −28.3% −28.3% 0% 1 — — Not enough years
Purchases, 12 months after the report 1 −35.9% −35.9% 0% 1 — — Not enough years
Purchases, 12 months after the trade 1 −38.0% −38.0% 0% 1 — — Not enough years
Sales, 3 months after the report 13 −6.1% −12.0% 69% 12 −1.44 0.18 No reliable evidence
Sales, 12 months after the report 12 −10.6% −18.2% 67% 11 −0.91 0.38 No reliable evidence
Sales, 12 months after the trade 12 −9.9% −18.8% 67% 11 −0.83 0.42 No reliable evidence

“Average vs S&P 500” is the stock’s return including dividends minus the index’s over the same dates, from the close on the first trading day after the report, or from the close on the trade date. Only windows that have finished are counted. For sales, a negative figure means the stock lagged after it was sold, so selling was the right call (green). “Went the right way” is the share of purchases that beat the index, or of sales that trailed it. The t-statistic uses one average per year of reports, because one person’s trades bunch into the same stock and weeks, and needs trades in at least four different years; the p-value comes from the t distribution with that number of years (with four years, a t of 2 has p = 0.14). “Some evidence” means p under 5%, “strong evidence” p under 1% over at least six years.

Companies traded

CompanyTitle on the latest filingPurchasesSalesFirst reportLatest report
Jazz Pharmaceuticals plc JAZZ —012August 14, 2013August 15, 2023
Lifecore Biomedical, Inc. DE LFCR —10January 11, 2019January 11, 2019
Maze Therapeutics, Inc. MAZE —01January 8, 2026January 8, 2026

Trades and what followed

Moves are against the S&P 500; green means the trade went the insider’s way.

ReportedTradedCompanyTradeValue3 months after report12 months after report12 months after trade
January 8, 2026January 6, 2026 MAZE Sale $1,149,121 −31.1%not yetnot yet
August 15, 2023August 14, 2023 JAZZ Sale $171,457 −12.0%−47.5%−45.0%
August 9, 2022August 8, 2022 JAZZ Sale $165,876 −0.7%−19.3%−23.4%
August 10, 2021August 6, 2021 JAZZ Sale $193,236 −14.6%+10.4%+8.1%
November 6, 2020November 4, 2020 JAZZ Sale $1,918,000 +2.4%−43.4%−53.0%
August 10, 2020August 7, 2020 JAZZ Sale $117,185 +12.2%−17.1%−14.4%
August 12, 2019August 9, 2019 JAZZ Sale $98,482 −10.2%−29.8%−25.4%
January 11, 2019January 10, 2019 LFCR Purchase $11,230 −24.8%−35.9%−37.9%
August 13, 2018August 10, 2018 JAZZ Sale $116,563 −12.2%−27.7%−27.7%
August 14, 2017August 11, 2017 JAZZ Sale $94,248 −12.2%+2.2%+5.2%
August 17, 2016August 15, 2016 JAZZ Sale $86,373 −18.2%−7.2%−8.5%
August 11, 2015August 10, 2015 JAZZ Sale $260,473 −26.2%−31.7%−23.2%
August 14, 2014August 12, 2014 JAZZ Sale $230,483 +12.0%+16.1%+28.4%
August 14, 2013August 14, 2013 JAZZ Sale $51,853 +31.6%+67.8%+59.9%

Open-market purchases and sales of at least $10,000 in companies we cover, from SEC Form 4 filings; sales made under a pre-set Rule 10b5-1 plan are not shown. “Not yet” means the window has not finished or the share price was under $5 at entry. These are the shares’ moves after each trade: they say nothing about why Sohn Catherine A. traded and do not suggest the use of non-public information. How every insider compares · the insider trading backtest.